

Tim Waterboer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2689975/publications.pdf>

Version: 2024-02-01

153
papers

4,823
citations

136950

32
h-index

118850

62
g-index

155
all docs

155
docs citations

155
times ranked

5015
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced Endometrial Ascension and Enhanced Reinfection Associated With Immunoglobulin G Antibodies to Specific <i>Chlamydia trachomatis</i> Proteins in Women at Risk for Chlamydia. <i>Journal of Infectious Diseases</i> , 2022, 225, 846-855.	4.0	5
2	Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 74, 1191-1198.	5.8	330
3	Associations between markers of social functioning and depression and quality of life in survivors of head and neck cancer: Findings from the Head and Neck Cancer 5000 study. <i>Psycho-Oncology</i> , 2022, 31, 478-485.	2.3	16
4	Reply to "Correspondence of Fernández-de-las-Peñas". <i>Clinical Infectious Diseases</i> , 2022, , .	5.8	0
5	Investigating the effect of sexual behaviour on oropharyngeal cancer risk: a methodological assessment of Mendelian randomization. <i>BMC Medicine</i> , 2022, 20, 40.	5.5	9
6	Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany. <i>BMC Infectious Diseases</i> , 2022, 22, 44.	2.9	1
7	Natural History of Incident and Persistent Cutaneous Human Papillomavirus and Human Polyomavirus Infections. <i>Journal of Infectious Diseases</i> , 2022, , .	4.0	2
8	Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer. <i>Clinical Epigenetics</i> , 2022, 14, 1.	4.1	17
9	DNA methylation-derived systemic inflammation indices and their association with oropharyngeal cancer risk and survival. <i>Head and Neck</i> , 2022, 44, 904-913.	2.0	2
10	Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis. <i>Cancer Epidemiology</i> , 2022, 77, 102117.	1.9	2
11	Mycobacterial infection aggravates <i>Helicobacter pylori</i> -induced gastric preneoplastic pathology by redirection of de novo induced Treg cells. <i>Cell Reports</i> , 2022, 38, 110359.	6.4	6
12	Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay. <i>Microbiology Spectrum</i> , 2022, 10, e0148021.	3.0	9
13	Prospective investigation of herpesvirus infection and risk of glioma. <i>International Journal of Cancer</i> , 2022, 151, 222-228.	5.1	3
14	HPV types 16/18 L1 E6 and E7 proteins seropositivity and cervical cancer risk in HIV-positive and HIV-negative black South African women. <i>Infectious Agents and Cancer</i> , 2022, 17, 14.	2.6	3
15	Association of Plasma Circulating Tumor HPV DNA With HPV-Related Oropharynx Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 488.	2.2	11
16	Human cytomegalovirus alters immune cell profile with potential implications for patient survival in head and neck cancer. <i>Carcinogenesis</i> , 2022, , .	2.8	0
17	Association of <i>Helicobacter pylori</i> and Autoimmune Gastritis With Stomach Cancer in a Cohort of Young Finnish Women. <i>Gastroenterology</i> , 2022, 163, 305-307.e4.	1.3	8
18	Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. <i>Nature Communications</i> , 2022, 13, 1818.	12.8	28

#	ARTICLE	IF	CITATIONS
19	Lifestyle factors associated with sex differences in Kaposi sarcoma incidence among adult black South Africans: A case-control study. <i>Cancer Epidemiology</i> , 2022, 78, 102158.	1.9	1
20	Health impact of seven herpesviruses on (pre)diabetes incidence and HbA1c: results from the KORA cohort. <i>Diabetologia</i> , 2022, 65, 1328-1338.	6.3	7
21	Using machine learning to predict COVID-19 infection and severity risk among 4510 aged adults: a UK Biobank cohort study. <i>Scientific Reports</i> , 2022, 12, 7736.	3.3	11
22	Epidemiology of Kaposi's sarcoma in sub-Saharan Africa. <i>Cancer Epidemiology</i> , 2022, 78, 102167.	1.9	14
23	Sero-prevalence of 19 infectious pathogens and associated factors among middle-aged and elderly Chinese adults: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e058353.	1.9	5
24	Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. <i>Journal of Clinical Oncology</i> , 2022, 40, 3613-3622.	1.6	14
25	Detection of HPV16 /18 E6 Oncoproteins in Head and Neck Squamous Cell Carcinoma Using a Protein Immunochromatographic Assay. <i>Laryngoscope</i> , 2021, 131, 1042-1048.	2.0	6
26	Cutaneous viral infections associated with ultraviolet radiation exposure. <i>International Journal of Cancer</i> , 2021, 148, 448-458.	5.1	8
27	Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer. <i>Cancer</i> , 2021, 127, 1029-1038.	4.1	41
28	<scp><i>Toxoplasma gondii</i></scp> infection and the risk of adult glioma in two prospective studies. <i>International Journal of Cancer</i> , 2021, 148, 2449-2456.	5.1	18
29	Inequality in survival of people with head and neck cancer: Head and Neck 5000 cohort study. <i>Head and Neck</i> , 2021, 43, 1252-1270.	2.0	8
30	Prediagnostic Antibody Responses to <i>Fusobacterium nucleatum</i> Proteins Are Not Associated with Risk of Colorectal Cancer in a Large U.S. Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1279-1282.	2.5	3
31	Survival advantage in patients with human papillomavirus-driven oropharyngeal cancer and variation by demographic characteristics and serologic response: Findings from Head and Neck 5000. <i>Cancer</i> , 2021, 127, 2442-2452.	4.1	8
32	From Multiplex Serology to Serolomics—A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome. <i>Viruses</i> , 2021, 13, 749.	3.3	11
33	Prospective investigation of polyomavirus infection and the risk of adult glioma. <i>Scientific Reports</i> , 2021, 11, 9642.	3.3	5
34	Sensitivity and Specificity of Human Papillomavirus (HPV) 16 Early Antigen Serology for HPV-Driven Oropharyngeal Cancer: A Systematic Literature Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3010.	3.7	19
35	Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case-control study. <i>European Journal of Neurology</i> , 2021, 28, 3072-3079.	3.3	20
36	Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1761-1764.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas. <i>Cancer Research</i> , 2021, 81, 4628-4638.	0.9	15
38	Trends in, and predictors of, swallowing and social eating outcomes in head and neck cancer survivors: A longitudinal analysis of head and neck 5000. <i>Oral Oncology</i> , 2021, 118, 105344.	1.5	7
39	Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of <i>Helicobacter pylori</i> CagA serostatus. <i>Oncogene</i> , 2021, 40, 5963-5969.	5.9	2
40	A Case Control Study of the Seroprevalence of <i>Helicobacter pylori</i> Proteins and Their Association with Pancreatic Cancer Risk. <i>Journal of Pancreatic Cancer</i> , 2021, 7, 57-64.	0.9	5
41	Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1458-1468.	9.1	28
42	Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2021, 121, 105461.	1.5	2
43	Association of Pre-diagnostic Antibody Responses to <i>Escherichia coli</i> and <i>Bacteroides fragilis</i> Toxin Proteins with Colorectal Cancer in a European Cohort. <i>Gut Microbes</i> , 2021, 13, 1-14.	9.8	19
44	Immunostimulatory membrane proteins potentiate <i>H. pylori</i> -induced carcinogenesis by enabling CagA translocation. <i>Gut Microbes</i> , 2021, 13, 1-13.	9.8	6
45	Reply to Peluso, et al. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	5
46	Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. <i>Nature Communications</i> , 2021, 12, 5945.	12.8	10
47	Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	7
48	Development of High-Throughput Multiplex Serology to Detect Serum Antibodies against <i>Coxiella burnetii</i> . <i>Microorganisms</i> , 2021, 9, 2373.	3.6	3
49	The relative and attributable risks of cardia and non-cardia gastric cancer associated with <i>Helicobacter pylori</i> infection in China: a case-cohort study. <i>Lancet Public Health</i> , The, 2021, 6, e888-e896.	10.0	78
50	Ranking lifestyle risk factors for cervical cancer among Black women: A case-control study from Johannesburg, South Africa. <i>PLoS ONE</i> , 2021, 16, e0260319.	2.5	5
51	Cutaneous $\hat{1}^2$ HPVs, Sun Exposure, and Risk of Squamous and Basal Cell Skin Cancers in Australia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , .	2.5	5
52	Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. <i>International Journal of Cancer</i> , 2020, 146, 2166-2174.	5.1	8
53	Viruses in Skin Cancer (VIRUSCAN): Study Design and Baseline Characteristics of a Prospective Clinic-Based Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 39-48.	2.5	7
54	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. <i>International Journal of Cancer</i> , 2020, 147, 757-765.	5.1	5

#	ARTICLE	IF	CITATIONS
55	Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age. <i>Oral Oncology</i> , 2020, 101, 104522.	1.5	19
56	Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 381-388.	1.1	2
57	Performance of multiplex serology in discriminating active vs past <i>Helicobacter pylori</i> infection in a primarily African American population in the southeastern United States. <i>Helicobacter</i> , 2020, 25, e12671.	3.5	12
58	Associations between <i>Helicobacter pylori</i> with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. <i>Helicobacter</i> , 2020, 25, e12756.	3.5	16
59	Association of Combined Sero-Positivity to <i>Helicobacter pylori</i> and <i>Streptococcus gallolyticus</i> with Risk of Colorectal Cancer. <i>Microorganisms</i> , 2020, 8, 1698.	3.6	4
60	Characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank. <i>EBioMedicine</i> , 2020, 62, 103123.	6.1	21
61	Early Detection of Human Papillomavirus-Driven Oropharyngeal Cancer Using Serology From the Study of Prevention of Anal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1806.	7.1	10
62	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	31
63	Racial Differences in <i>Helicobacter pylori</i> CagA Sero-prevalence in a Consortium of Adult Cohorts in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2084-2092.	2.5	18
64	Humoral Response to HPV16 Proteins in Persons with Anal High-Grade Squamous Intraepithelial Lesion or Anal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2255-2260.	2.5	3
65	HPV cervical infections and serological status in vaccinated and unvaccinated women. <i>Vaccine</i> , 2020, 38, 8167-8174.	3.8	9
66	Antibody Responses to <i>Helicobacter pylori</i> and Risk of Developing Colorectal Cancer in a European Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1475-1481.	2.5	11
67	HPV driven squamous cell head and neck cancer of unknown primary is likely to be HPV driven squamous cell oropharyngeal cancer. <i>Oral Oncology</i> , 2020, 107, 104721.	1.5	10
68	High Ambient Solar UV Correlates with Greater Beta HPV Seropositivity in New South Wales, Australia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 49-56.	2.5	3
69	Johannesburg Cancer Study (JCS): contribution to knowledge and opportunities arising from 20 years of data collection in an African setting. <i>Cancer Epidemiology</i> , 2020, 65, 101701.	1.9	11
70	Patient-reported swallowing function after treatment for early-stage oropharyngeal carcinoma: Population-based study. <i>Head and Neck</i> , 2020, 42, 1981-1993.	2.0	2
71	Molecular profiling of gastric cancer in a population with high HIV prevalence reveals a shift to MLH1 loss but not the EBV subtype. <i>Cancer Medicine</i> , 2020, 9, 3445-3454.	2.8	3
72	Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 414-419.	2.5	8

#	ARTICLE	IF	CITATIONS
73	Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	14
74	Identifying epigenetic biomarkers of established prognostic factors and survival in a clinical cohort of individuals with oropharyngeal cancer. <i>Clinical Epigenetics</i> , 2020, 12, 95.	4.1	6
75	Seropositivity for <i>Helicobacter pylori</i> and hepatobiliary cancers in the PLCO study. <i>British Journal of Cancer</i> , 2020, 123, 909-911.	6.4	6
76	Risk factors for human papillomavirus-positive nonoropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 1954-1962.	2.0	6
77	Disease trajectories, place and mode of death in people with head and neck cancer: Findings from the "Head and Neck 5000" population-based prospective clinical cohort study. <i>Palliative Medicine</i> , 2020, 34, 639-650.	3.1	14
78	Serologic markers of <i>Chlamydia trachomatis</i> and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort. <i>International Journal of Cancer</i> , 2020, 147, 2042-2052.	5.1	26
79	Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country. <i>International Journal of Cancer</i> , 2020, 147, 461-471.	5.1	16
80	Differences in antibody levels to <i>H. pylori</i> virulence factors VacA and CagA among African Americans and whites in the Southeast USA. <i>Cancer Causes and Control</i> , 2020, 31, 601-606.	1.8	13
81	Seropositivity of selected chronic infections and different measures of obesity. <i>PLoS ONE</i> , 2020, 15, e0231974.	2.5	3
82	Epigenetic prediction of complex traits and mortality in a cohort of individuals with oropharyngeal cancer. <i>Clinical Epigenetics</i> , 2020, 12, 58.	4.1	8
83	Comparison of a VLP-based and GSTL1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine. <i>Journal of Medical Virology</i> , 2020, 92, 3774-3783.	5.0	8
84	Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2729-2734.	2.5	5
85	Serological and hematological characteristics of Sjogren's syndrome and dry eye syndrome patients using a novel immune serology technique. <i>PLoS ONE</i> , 2020, 15, e0244712.	2.5	1
86	Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test. <i>EBioMedicine</i> , 2020, 62, 103143.	6.1	2
87	Development of <i>Helicobacter pylori</i> Whole-Proteome Arrays and Identification of Serologic Biomarkers for Noncardia Gastric Cancer in the MCC-Spain Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2235-2242.	2.5	4
88	Antibodies Against <i>Chlamydia trachomatis</i> and Ovarian Cancer Risk in Two Independent Populations. <i>Journal of the National Cancer Institute</i> , 2019, 111, 129-136.	6.3	56
89	Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16955-16960.	7.1	120
90	Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. <i>International Journal of Cancer</i> , 2019, 145, 3436-3444.	5.1	8

#	ARTICLE	IF	CITATIONS
91	Antibody responses to flagellin C and Streptococcus gallolyticus pilus proteins in colorectal cancer. Scientific Reports, 2019, 9, 10847.	3.3	3
92	Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer. Cancer Prevention Research, 2019, 12, 689-700.	1.5	32
93	Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization. Journal of Clinical Microbiology, 2019, 57, .	3.9	8
94	Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. Clinical Cancer Research, 2019, 25, 7405-7412.	7.0	13
95	Antibody Responses to <i>Fusobacterium nucleatum</i> Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1552-1555.	2.5	17
96	Dietary behaviors and survival in people with head and neck cancer: Results from Head and Neck 5000. Head and Neck, 2019, 41, 2074-2084.	2.0	5
97	Validation of monoplex assays detecting antibodies against Corynebacterium diphtheriae and Clostridium tetani toxins, rubella virus and parvovirus B19 for incorporation into Multiplex Serology. Methods, 2019, 158, 44-53.	3.8	4
98	Sex differences in HPV immunity among adults without cancer. Human Vaccines and Immunotherapeutics, 2019, 15, 1935-1941.	3.3	13
99	Epstein Barr virus antibody reactivity and gastric cancer: A population-based case-control study. Cancer Epidemiology, 2019, 61, 79-88.	1.9	8
100	Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study. BMJ Open, 2019, 9, e025129.	1.9	17
101	Risk factors for herpes simplex virus type-1 infection and reactivation: Cross-sectional studies among EPIC-Norfolk participants. PLoS ONE, 2019, 14, e0215553.	2.5	15
102	Helicobacter pylori Seropositivity: Prevalence, Associations, and the Impact on Incident Metabolic Diseases/Risk Factors in the Population-Based KORA Study. Frontiers in Public Health, 2019, 7, 96.	2.7	13
103	First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions. Journal of Clinical Virology, 2019, 117, 11-18.	3.1	14
104	Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies. British Journal of Cancer, 2019, 120, 855-860.	6.4	23
105	Post-treatment human papillomavirus antibody kinetics in cervical cancer patients. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180295.	4.0	6
106	Serological Assessment of 18 Pathogens and Risk of AIDS-Associated Non-Hodgkin Lymphoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e53-e63.	2.1	5
107	P611...High seroprevalence of mycoplasma genitalium in the general adult population of Germany. , 2019, , .		0
108	Smoking, <i>Helicobacter Pylori</i> Serology, and Gastric Cancer Risk in Prospective Studies from China, Japan, and Korea. Cancer Prevention Research, 2019, 12, 667-674.	1.5	33

#	ARTICLE	IF	CITATIONS
109	Chlamydia trachomatis Whole-Proteome Microarray Analysis of The Netherlands Chlamydia Cohort Study. <i>Microorganisms</i> , 2019, 7, 703.	3.6	9
110	Increased Serological Response Against Human Herpesvirus 6A Is Associated With Risk for Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 2715.	4.8	63
111	Concordance of Self- and Clinician-Collected Anal Swabs to Detect Human Papillomavirus in a Sample of HIV-Negative Men. <i>Journal of Lower Genital Tract Disease</i> , 2019, 23, 200-204.	1.9	6
112	Virological and Serological Predictors of Anal High-grade Squamous Intraepithelial Lesions Among Human Immunodeficiency Virus-positive Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2019, 68, 1377-1387.	5.8	11
113	Association between comorbidity and survival in head and neck cancer: Results from Head and Neck 5000. <i>Head and Neck</i> , 2019, 41, 1053-1062.	2.0	32
114	Bacterial Translocation and Risk of Liver Cancer in a Finnish Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 807-813.	2.5	23
115	Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and <i>Toxoplasma gondii</i> . <i>PLoS ONE</i> , 2019, 14, e0210407.	2.5	18
116	Serologic Response to <i>Helicobacter pylori</i> Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. <i>Gastroenterology</i> , 2019, 156, 175-186.e2.	1.3	84
117	High Levels of Epstein-Barr Virus Nuclear Antigen-1-Specific Antibodies and Infectious Mononucleosis Act Both Independently and Synergistically to Increase Multiple Sclerosis Risk. <i>Frontiers in Neurology</i> , 2019, 10, 1368.	2.4	49
118	In situ, Cell-free Protein Expression on Microarrays and Their Use for the Detection of Immune Responses. <i>Bio-protocol</i> , 2019, 9, e3152.	0.4	5
119	Screening for human papillomavirus-driven oropharyngeal cancer: Considerations for feasibility and strategies for research. <i>Cancer</i> , 2018, 124, 1859-1866.	4.1	48
120	Human Papillomavirus Seroprevalence and Association with Anal HPV Infection and Squamous Intraepithelial Lesions in Australian Gay and Bisexual Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 768-775.	2.5	7
121	Validation of Multiplex Serology detecting human herpesviruses 1-5. <i>PLoS ONE</i> , 2018, 13, e0209379.	2.5	39
122	Differences in <i>Chlamydia trachomatis</i> seroprevalence between ethnic groups cannot be fully explained by socioeconomic status, sexual healthcare seeking behavior or sexual risk behavior: a cross-sectional analysis in the HEalthy Life in an Urban Setting (HELIUS) study. <i>BMC Infectious Diseases</i> , 2018, 18, 612.	2.9	12
123	Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer. <i>Oral Oncology</i> , 2018, 82, 108-114.	1.5	26
124	Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. <i>Oral Oncology</i> , 2017, 67, 77-82.	1.5	28
125	Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	77
126	Human papillomavirus 16 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. <i>Cancer</i> , 2017, 123, 4382-4390.	4.1	67

#	ARTICLE	IF	CITATIONS
127	Prospective Study of Human Polyomaviruses and Risk of Cutaneous Squamous Cell Carcinoma in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 736-744.	2.5	5
128	Human Papillomavirus Antibodies and Future Risk of Anogenital Cancer: A Nested Case-Control Study in the European Prospective Investigation Into Cancer and Nutrition Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 877-884.	1.6	53
129	Hepatitis C Virus Seroprevalence in Mongolian Women Assessed by a Novel Multiplex Antibody Detection Assay. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1360-1365.	2.5	14
130	Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 683-689.	2.5	54
131	Amino Acid Variation in HLA Class II Proteins Is a Major Determinant of Humoral Response to Common Viruses. <i>American Journal of Human Genetics</i> , 2015, 97, 738-743.	6.2	63
132	<i>Helicobacter pylori</i> antibody patterns in Germany: a cross-sectional population study. <i>Gut Pathogens</i> , 2014, 6, 10.	3.4	42
133	Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. <i>International Journal of Cancer</i> , 2014, 135, 2453-2461.	5.1	51
134	Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2708-2715.	1.6	280
135	Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: A population-based study. <i>International Journal of Cancer</i> , 2013, 133, 1713-1720.	5.1	60
136	Case-Control Study of Cutaneous Human Papillomavirus Infection in Basal Cell Carcinoma of the Skin. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1512-1520.	0.7	48
137	Human Papillomavirus Load in Eyebrow Hair Follicles and Risk of Cutaneous Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 719-727.	2.5	84
138	Case-control Study of Merkel Cell Polyomavirus Infection and Cutaneous Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 74-81.	2.5	54
139	Prospective Study of Human Papillomavirus Seropositivity and Risk of Nonmelanoma Skin Cancer. <i>American Journal of Epidemiology</i> , 2012, 175, 685-695.	3.4	50
140	Case-Control Study of Cutaneous Human Papillomaviruses in Squamous Cell Carcinoma of the Skin. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1303-1313.	2.5	64
141	The Association between Cutaneous Squamous Cell Carcinoma and Betapapillomavirus Seropositivity: a Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1171-1177.	2.5	24
142	Lack of association between the presence and persistence of betapapillomavirus DNA in eyebrow hairs and betapapillomavirus L1 antibodies in serum. <i>Journal of General Virology</i> , 2010, 91, 2073-2079.	2.9	9
143	Risk Factors for Cutaneous Human Papillomavirus Seroreactivity among Patients Undergoing Skin Cancer Screening in Florida. <i>Journal of Infectious Diseases</i> , 2010, 201, 760-769.	4.0	26
144	Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. <i>Journal of General Virology</i> , 2010, 91, 1849-1853.	2.9	118

#	ARTICLE	IF	CITATIONS
145	Multicenter Study of the Association between Betapapillomavirus Infection and Cutaneous Squamous Cell Carcinoma. <i>Cancer Research</i> , 2010, 70, 9777-9786.	0.9	130
146	Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia. <i>Journal of General Virology</i> , 2009, 90, 1986-1998.	2.9	47
147	<i>Helicobacter pylori</i> Multiplex Serology. <i>Helicobacter</i> , 2009, 14, 525-535.	3.5	112
148	The sero-epidemiology of human papillomavirus among Caucasian transplant recipients in the UK. <i>Infectious Agents and Cancer</i> , 2009, 4, 13.	2.6	14
149	Seroprevalence of 34 Human Papillomavirus Types in the German General Population. <i>PLoS Pathogens</i> , 2008, 4, e1000091.	4.7	145
150	Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 189-195.	2.5	76
151	Human Papillomavirus Infection and Incidence of Squamous Cell and Basal Cell Carcinomas of the Skin. <i>Journal of the National Cancer Institute</i> , 2006, 98, 389-395.	6.3	229
152	Suppression of non-specific binding in serological Luminex assays. <i>Journal of Immunological Methods</i> , 2006, 309, 200-204.	1.4	251
153	Multiplex Human Papillomavirus Serology Based on In Situ Purified Glutathione S-Transferase Fusion Proteins. <i>Clinical Chemistry</i> , 2005, 51, 1845-1853.	3.2	486